BioSpace News Archive

Point-of-care testing for glucose monitoring is a valuable tool for managing patients with diabetes in the outpatient settings.

The demand within the global market for life science microscopy devices has been rising on account of advancements in the domain of medical research and development, finds Transparency Market Research.

The global market for biological safety testing is showcasing a highly competitive business structure, finds a new research study by Transparency Market Research.

The global phototherapy equipment market is highly competitive in nature and is expected to witness an increased level of competition throughout the forecast period, states a new research report by Transparency Market Research.

Transparency Market Research observes, the Malaysia medical tourism market is highly competitive due to presence of number of companies operating in the market.

The world bioreactors and fermenters market is characterized with a largely consolidated business landscape and a low to moderate level of market competition, with the top five players holding for a more than around 63% of the said market in 2015, as noted by Transparency Market Research in its recent report.

Ultimovacs ASA, a clinical stage leader in immune stimulatory vaccines for cancer, announced that the first patient has been enrolled in FOCUS, an investigator-led Phase II randomized clinical trial in head-and-neck cancer of the Company’s telomerase cancer vaccine, UV1, in combination with the checkpoint inhibitor pembrolizumab.

Medivir AB announces that an e-poster entitled “Phase 1 study of the novel prodrug MIV-818 in patients with hepatocellular carcinoma, intrahepatic cholangiocarcinoma or liver metastases " will be presented by Dr Debashis Sarker, King´s College London, at the European Society for Medical Oncology congress.

HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced that pre-clinical data on its replicating Lymphocytic choriomeningitis arenaviral-based immunotherapeutic has been published in the peer-reviewed journal, Nature Communications.

The Phase 3 trial of Sanofi and Regeneron’s PD-1 inhibitor Libtayo in combination with platinum-doublet chemotherapy was stopped early after meeting its overall survival primary endpoint in patients with advanced non-small cell lung cancer.